The CLL treatment landscape is evolving in Canada. Recent data, funding/drug approval updates, and integration of novel agents have made clinical decisions more complex. To provide context and guidance on how to navigate some of the challenges that specialists face in routine practice, CARE™ Faculty are developing a series of case studies.
The first issue in the series explores identification and management of relapse after BTK inhibition. Profile and discussion content in Issue 1: Parts 1 & 2 was provided by Dr. Peter Anglin, CARE™ Hematology Faculty Lead.
This publication focuses on relapse post-Ibrutinib treatment in front-line.
This publication is a continuation of the case study presented in the first issue and provides information on next steps for managing a patient that has experienced failure on front-line BCRi therapy with Ibrutinib.